A Single-dose, Open-label, Parallel Study to Assess the Pharmacokinetics of AFQ056 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2013
At a glance
- Drugs Mavoglurant (Primary)
- Indications Chorea; Drug-induced dyskinesia; Fragile X syndrome; Gastro-oesophageal reflux
- Focus Pharmacokinetics
- 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Apr 2012 Planned End Date changed from 1 Nov 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
- 26 Oct 2011 New trial record